Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients

Oncology Reports

Volumn 18, Issue 5, 2007, Pages 1321-1327

  Festuccia, Claudio ^a   Gravina, Giovanni Luca ^a   Muzi, Paola ^a   Biordi, Leda ^a   Ronchi, Piero ^a   Martella, Oreste ^a   Vicentini, Carlo ^a   Bologna, Mauro ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Epidermal growth factor receptor; Her2; Hormone refractory prostate cancer; Hormone therapy

Indexed keywords

ANDROGEN; ANILIDE; ANTINEOPLASTIC AGENT; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; NITRILE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANDROGENS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; TOSYL COMPOUNDS;

EID: 38449106004     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.5.1321     Document Type: Article

References (43)

1. De Marzo AM, Putzi MJ and Nelson WG: New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57: 103-114, 2001.
2. Osman I, Scher HI, Drobnjak M, et al: C.HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7: 2643-2647, 2001. (Pubitemid 32911366)
3. Di Lorenzo G, Tortora G, D'Armiento FP, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444, 2002. (Pubitemid 35340719)
4. Calvo BF, Levine AM, Marcos M, et al: Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 9: 1087-1097, 2003. (Pubitemid 36323716)
5. Hernes E, Fossa SD, Berner A, et al: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 90: 449-454, 2004. (Pubitemid 38250644)
6. Osman I, Mikhail M, Shuch B, et al: Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 174: 2174-2177, 2005. (Pubitemid 41611768)
7. Okegawa T, Kinjo M, Nutahara K and Higashihara E: Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 13: 1197-1201, 2006. (Pubitemid 44410909)
8. Montironi R, Mazzucchelli R, Barbisan F, et al: HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Hum Pathol 37: 1137-1144, 2006. (Pubitemid 44286977)
9. Gregory CW, Whang YE, McCall W, et al: Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11: 1704-1712, 2005. (Pubitemid 40471831)
10. Liu Y, Majumder S, McCall W, et al: Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 65: 3404-3409, 2005. (Pubitemid 40524626)
11. Berger R, Lin DI, Nieto M, et al: Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 66: 5723-5728, 2006. (Pubitemid 43927125)
12. Lara PN Jr, Chee KG, Longmate J, et al: Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100: 2125-2131, 2004. (Pubitemid 38580330)
13. Ziada A, Barqawi A, Glode LM, et al: The use of trastuzumab in the treatment of hormone refractory prostate cancer: phase II trial. Prostate 60: 332-337, 2004. (Pubitemid 39050653)
14. de Bono JS, Bellmunt J, Attard G, Droz JP, et al: Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262, 2007. (Pubitemid 350003013)
15. Agus DB, Sweeney CJ, Morris MJ, et al: Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25: 675-681, 2007. (Pubitemid 350002923)
16. Agus DB, Scher HI, Higgins B, et al: Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and - independent human xenograft models. Cancer Res 59: 4761-4764, 1999. (Pubitemid 29472871)
17. DeGrendele H: The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer. Clin Prostate Cancer 2: 143-145, 2003.
18. Edwards J, Traynor P, Munro AF, et al: The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 12: 123-130, 2006. (Pubitemid 43166185)
19. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053-2063, 2000. (Pubitemid 30305105)
20. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000. (Pubitemid 32110433)
21. Ciardiello F, Caputo R, Bianco R, et al: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001. (Pubitemid 32708703)
22. Moasser MM, Basso A, Averbuch SD and Rosen N: The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61: 7184-7188, 2001. (Pubitemid 32946513)
23. Moulder SL, Yakes FM, Muthuswamy SK, et al: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61: 8887-8895, 2001. (Pubitemid 34013905)
24. Bianco C, Tortora G, Bianco R, et al: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8: 3250-3258, 2002. (Pubitemid 35155038)
25. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR and Tortora G: ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98: 463-469, 2002. (Pubitemid 34188692)
26. Fujimura M, Hidaka T and Saito S: Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res 8: 2448-2454, 2002. (Pubitemid 34753622)
27. Huang SM, Li J, Armstrong EA and Harari PM: Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62: 4300-4306, 2002. (Pubitemid 34827286)
28. Janne PA, Taffaro ML, Salgia R and Johnson BE: Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62: 5242-5247, 2002. (Pubitemid 35024597)
29. Magne N, Fischel JL, Dubreuil A, et al: Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86: 819-827, 2002. (Pubitemid 34250828)
30. Williams KJ, Telfer BA, Stratford IJ and Wedge SR: ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86: 1157-1161, 2002. (Pubitemid 34438090)
31. Bologna M, Vicentini C, Festuccia C, et al: Early diagnosis of prostatic carcinoma based on in vitro culture of viable tumor cells harvested by prostatic massage. Eur Urol 14: 474-476, 1988.
32. Bologna M, Vicentini C, Festuccia C, et al: Short-term tissue culture of prostatic carcinoma samples provides useful biological parameters related to patient prognosis. Eur Urol 15: 243-247, 1988. (Pubitemid 19006573)
33. Festuccia C, Angelucci A, Gravina GL, et al: Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Int J Oncol 26: 1353-1362, 2005.
34. Vicentini C, Gravina GL, Angelucci A, et al: Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 130: 217-221, 2004. (Pubitemid 38553630)
35. Festuccia C, Muzi P, Millimaggi D, et al: Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 12: 983-998, 2005. (Pubitemid 41815791)
36. Helfrich BA, Raben D, Varella-Garcia M, et al: Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12: 7117-7125, 2006. (Pubitemid 44974512)
37. Parra HS, Cavina R, Latteri F, et al: Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91: 208-212, 2004. (Pubitemid 39037060)
38. Festuccia C, Gravina GL, Angelucci A, et al: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer 115: 630-640, 2005 (Pubitemid 40656723)
39. Gravina GL, Festuccia C, Angelucci A, et al: Long-term presence of androgens and anti-androgens modulate EGF-receptor expression and MAP-kinase phosphorylation in androgen receptor-prostate positive cancer cells. Int J Oncol 25: 97-104, 2004.
40. Gravina GL, Festuccia C, Paradiso Galatioto G, et al: Bicalutamide before surgery induces changes in tumor molecular arrangements and reduces the positive margins in prostate cancers. Urology (In press).
41. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648, 1999. (Pubitemid 29415219)
42. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
43. Bonaccorsi L, Nosi D, Muratori M, Formigli L, Forti G and Baldi E: Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol 38: 51-66, 2007. (Pubitemid 46351592)